This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A long-acting amylin receptor agonist that targets satiety via the brainstem — a fundamentally different pathway from GLP-1. Developed as part of Novo Nordisk's CagriSema program, cagrilintide shows additive weight loss effects when combined with semaglutide because the two peptides act on separate receptor systems. In Phase 2 monotherapy trials, it produced ~15% weight loss. In combination with semaglutide in the REDEFINE program, up to 22%.
Amylin is a 37-amino acid peptide co-secreted by pancreatic beta cells alongside insulin after meals. It acts on the amylin receptor complex (CALCR + RAMP1) in the area postrema and nucleus tractus solitarius of the brainstem — the satiety and nausea regulation centers — to slow gastric emptying, suppress glucagon, and signal fullness to the hypothalamus. Native amylin has a half-life of minutes; cagrilintide is a chemically stabilized long-acting analogue engineered for once-weekly dosing.
The critical distinction: cagrilintide does not touch the GLP-1 receptor. It works upstream through amylinergic signaling, which means its satiety effects are additive to GLP-1 agonists rather than redundant. This is the pharmacologic rationale behind CagriSema — Novo Nordisk's fixed-ratio combination of cagrilintide and semaglutide currently in Phase 3 REDEFINE trials.
As a standalone research peptide, cagrilintide is studied for satiety regulation, weight management, and metabolic health in individuals who want amylinergic signaling support without the GI profile of GLP-1 agonists, or who are looking to combine both mechanisms.
Because the two systems operate via different receptors in different brain regions, their satiety effects sum rather than cancel. The REDEFINE 1 trial demonstrated this directly: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) produced ~22% weight loss at 68 weeks — meaningfully greater than semaglutide alone (~14%) in comparable trials.
Phase 2 monotherapy trials at 2.4mg/week showed ~15% body weight reduction over 26 weeks. Phase 3 combination data (REDEFINE 1) showed ~22% in combination with semaglutide — the additive signal is the key finding.
Amylin receptors in the brainstem regulate the "I'm full" signal at the neurological level. Unlike GLP-1 hypothalamic signaling, brainstem amylinergic satiety tends to have a lower nausea burden at therapeutic doses — a meaningful tolerability distinction.
Post-meal glucagon spikes drive hepatic glucose output and fat mobilization in a metabolically unhelpful direction. Amylin/cagrilintide suppresses this glucagon spike independently of insulin — relevant for metabolic syndrome and insulin resistance research.
Cagrilintide slows gastric transit via vagal amylinergic pathways, extending the window of nutrient absorption and prolonging satiety signaling. Effect is distinct from and complementary to GLP-1-mediated gastric slowing.
Weight reduction of 15–22% produces secondary improvements in lipid panels, blood pressure, HbA1c, and inflammatory markers. REDEFINE trials include cardiometabolic endpoints; full results are anticipated 2025–2026.
The mechanistic case for combining amylin + GLP-1 signaling is strong and backed by REDEFINE data. For researchers studying both pathways, cagrilintide pairs with semaglutide or tirzepatide without receptor overlap or pharmacokinetic interference.
Body weight reduction in Phase 2 dose-finding trial at 2.4mg/week over 26 weeks. Statistically significant vs placebo; comparable to early semaglutide dose-ranging data.
Weight loss at 68 weeks in REDEFINE 1 Phase 3 trial using cagrilintide 2.4mg + semaglutide 2.4mg weekly. Demonstrates genuine additive effect vs GLP-1 monotherapy.
The amylin receptor complex CALCR/RAMP1 is the molecular target. This is distinct from GLP-1R, GIP-R, and glucagon receptor — zero receptor overlap with the GLP-1 drug class.
Cagrilintide is a once-weekly subcutaneous injection. The therapeutic dose used in REDEFINE trials is 2.4mg/week reached via monthly titration to minimize GI side effects (nausea, vomiting) during the adjustment period. Titration matters — jumping to full dose is associated with poor tolerability.
| Titration Step | Dose | Duration | Notes |
|---|---|---|---|
| Week 1–4 | 0.25mg SC weekly | 4 weeks | Starting dose. GI adaptation period — nausea is most common at this stage and typically resolves. |
| Week 5–8 | 0.5mg SC weekly | 4 weeks | First escalation. Assess tolerability before advancing. |
| Week 9–12 | 1.0mg SC weekly | 4 weeks | Mid-titration. Meaningful satiety effects typically become apparent here. |
| Week 13–16 | 1.6mg SC weekly | 4 weeks | Pre-maintenance step. Tolerability assessment at each stage. |
| Week 17+ | 2.4mg SC weekly | Maintenance | Target maintenance dose used in REDEFINE trials. Cycle length: 24–52 weeks in trial protocols. |
Cagrilintide's zero GLP-1 receptor overlap makes it uniquely stackable with the GLP-1 class. The combination is not experimental — it is the mechanistic basis for the entire REDEFINE program. Other metabolic synergies:
Note: semaglutide and tirzepatide pages are currently waitlisted pending supply. Cagrilintide as a standalone amylinergic protocol is available now.
Third-party COA, Finnrick-verified purity. Available in 2.4mg vials. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.